|
nasdaq:vygr
|
5074064
|
Apr 21st, 2024 12:00AM
|
Voyager Therapeutics, Inc.
|
36K
|
193.00
|
Open
|
|
Apr 21st, 2024 03:27AM
|
Apr 21st, 2024 03:27AM
|
Voyager Therapeutics (Nasdaq: VYGR) is a biotechnology company dedicated to breaking through barriers in gene therapy and neurology. The potential of both disciplines has been constrained by delivery challenges; Voyager is leveraging cutting-edge expertise in capsid discovery and deep neuropharmacology capabilities to address these constraints. Voyager’s TRACER™ AAV capsid discovery platform has generated novel capsids with high target delivery and blood-brain barrier penetration at low doses, potentially addressing the narrow therapeutic window associated with conventional gene therapy delivery vectors. This platform is fueling alliances with Alexion (AstraZeneca Rare Disease); Novartis Pharma AG; Neurocrine Biosciences, Inc. and Sangamo Therapeutics, Inc., as well as multiple programs in Voyager’s own pipeline. Voyager’s pipeline includes wholly-owned and collaborative preclinical programs in Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and other diseases of the central nervous system, with a focus on validated targets and biomarkers to enable a path to rapid potential proof-of-biology. For more information, visit www.voyagertherapeutics.com.
|
Open
|
Gene Therapy, biotechnology, adeno associated virus, Research, Parkinson's Disease, Huntington's Disease, vector engineering, SF9, Alzheimer's disease, ALS, Amyotrophic Lateral Sclerosis, Friedrich's Ataxia, SOD-1, Tauopathies, gene therapy, Neurology, Neuropharmacology, and CNS
|
Open
|
64 Sidney St
|
Cambridge
|
Massachusetts
|
US
|
02139
|
|
Voyager Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:vygr
|
5074064
|
Apr 20th, 2024 12:00AM
|
Voyager Therapeutics, Inc.
|
36K
|
193.00
|
Open
|
|
Apr 20th, 2024 12:28AM
|
Apr 20th, 2024 05:49PM
|
Voyager Therapeutics (Nasdaq: VYGR) is a biotechnology company dedicated to breaking through barriers in gene therapy and neurology. The potential of both disciplines has been constrained by delivery challenges; Voyager is leveraging cutting-edge expertise in capsid discovery and deep neuropharmacology capabilities to address these constraints. Voyager’s TRACER™ AAV capsid discovery platform has generated novel capsids with high target delivery and blood-brain barrier penetration at low doses, potentially addressing the narrow therapeutic window associated with conventional gene therapy delivery vectors. This platform is fueling alliances with Alexion (AstraZeneca Rare Disease); Novartis Pharma AG; Neurocrine Biosciences, Inc. and Sangamo Therapeutics, Inc., as well as multiple programs in Voyager’s own pipeline. Voyager’s pipeline includes wholly-owned and collaborative preclinical programs in Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and other diseases of the central nervous system, with a focus on validated targets and biomarkers to enable a path to rapid potential proof-of-biology. For more information, visit www.voyagertherapeutics.com.
|
Open
|
Gene Therapy, biotechnology, adeno associated virus, Research, Parkinson's Disease, Huntington's Disease, vector engineering, SF9, Alzheimer's disease, ALS, Amyotrophic Lateral Sclerosis, Friedrich's Ataxia, SOD-1, Tauopathies, gene therapy, Neurology, Neuropharmacology, and CNS
|
Open
|
64 Sidney St
|
Cambridge
|
Massachusetts
|
US
|
02139
|
|
Voyager Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:vygr
|
5074064
|
Apr 19th, 2024 12:00AM
|
Voyager Therapeutics, Inc.
|
36K
|
193.00
|
Open
|
|
Apr 19th, 2024 04:50AM
|
Apr 19th, 2024 04:50AM
|
Voyager Therapeutics (Nasdaq: VYGR) is a biotechnology company dedicated to breaking through barriers in gene therapy and neurology. The potential of both disciplines has been constrained by delivery challenges; Voyager is leveraging cutting-edge expertise in capsid discovery and deep neuropharmacology capabilities to address these constraints. Voyager’s TRACER™ AAV capsid discovery platform has generated novel capsids with high target delivery and blood-brain barrier penetration at low doses, potentially addressing the narrow therapeutic window associated with conventional gene therapy delivery vectors. This platform is fueling alliances with Alexion (AstraZeneca Rare Disease); Novartis Pharma AG; Neurocrine Biosciences, Inc. and Sangamo Therapeutics, Inc., as well as multiple programs in Voyager’s own pipeline. Voyager’s pipeline includes wholly-owned and collaborative preclinical programs in Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and other diseases of the central nervous system, with a focus on validated targets and biomarkers to enable a path to rapid potential proof-of-biology. For more information, visit www.voyagertherapeutics.com.
|
Open
|
Gene Therapy, biotechnology, adeno associated virus, Research, Parkinson's Disease, Huntington's Disease, vector engineering, SF9, Alzheimer's disease, ALS, Amyotrophic Lateral Sclerosis, Friedrich's Ataxia, SOD-1, Tauopathies, gene therapy, Neurology, Neuropharmacology, and CNS
|
Open
|
64 Sidney St
|
Cambridge
|
Massachusetts
|
US
|
02139
|
|
Voyager Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:vygr
|
5074064
|
Apr 18th, 2024 12:00AM
|
Voyager Therapeutics, Inc.
|
36K
|
193.00
|
Open
|
|
Apr 18th, 2024 01:29AM
|
Apr 18th, 2024 07:09PM
|
Voyager Therapeutics (Nasdaq: VYGR) is a biotechnology company dedicated to breaking through barriers in gene therapy and neurology. The potential of both disciplines has been constrained by delivery challenges; Voyager is leveraging cutting-edge expertise in capsid discovery and deep neuropharmacology capabilities to address these constraints. Voyager’s TRACER™ AAV capsid discovery platform has generated novel capsids with high target delivery and blood-brain barrier penetration at low doses, potentially addressing the narrow therapeutic window associated with conventional gene therapy delivery vectors. This platform is fueling alliances with Alexion (AstraZeneca Rare Disease); Novartis Pharma AG; Neurocrine Biosciences, Inc. and Sangamo Therapeutics, Inc., as well as multiple programs in Voyager’s own pipeline. Voyager’s pipeline includes wholly-owned and collaborative preclinical programs in Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and other diseases of the central nervous system, with a focus on validated targets and biomarkers to enable a path to rapid potential proof-of-biology. For more information, visit www.voyagertherapeutics.com.
|
Open
|
Gene Therapy, biotechnology, adeno associated virus, Research, Parkinson's Disease, Huntington's Disease, vector engineering, SF9, Alzheimer's disease, ALS, Amyotrophic Lateral Sclerosis, Friedrich's Ataxia, SOD-1, Tauopathies, gene therapy, Neurology, Neuropharmacology, and CNS
|
Open
|
64 Sidney St
|
Cambridge
|
Massachusetts
|
US
|
02139
|
|
Voyager Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:vygr
|
5074064
|
Apr 17th, 2024 12:00AM
|
Voyager Therapeutics, Inc.
|
36K
|
193.00
|
Open
|
|
Apr 17th, 2024 04:27AM
|
Apr 17th, 2024 03:36PM
|
Voyager Therapeutics (Nasdaq: VYGR) is a biotechnology company dedicated to breaking through barriers in gene therapy and neurology. The potential of both disciplines has been constrained by delivery challenges; Voyager is leveraging cutting-edge expertise in capsid discovery and deep neuropharmacology capabilities to address these constraints. Voyager’s TRACER™ AAV capsid discovery platform has generated novel capsids with high target delivery and blood-brain barrier penetration at low doses, potentially addressing the narrow therapeutic window associated with conventional gene therapy delivery vectors. This platform is fueling alliances with Alexion (AstraZeneca Rare Disease); Novartis Pharma AG; Neurocrine Biosciences, Inc. and Sangamo Therapeutics, Inc., as well as multiple programs in Voyager’s own pipeline. Voyager’s pipeline includes wholly-owned and collaborative preclinical programs in Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and other diseases of the central nervous system, with a focus on validated targets and biomarkers to enable a path to rapid potential proof-of-biology. For more information, visit www.voyagertherapeutics.com.
|
Open
|
Gene Therapy, biotechnology, adeno associated virus, Research, Parkinson's Disease, Huntington's Disease, vector engineering, SF9, Alzheimer's disease, ALS, Amyotrophic Lateral Sclerosis, Friedrich's Ataxia, SOD-1, Tauopathies, gene therapy, Neurology, Neuropharmacology, and CNS
|
Open
|
64 Sidney St
|
Cambridge
|
Massachusetts
|
US
|
02139
|
|
Voyager Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:vygr
|
5074064
|
Apr 16th, 2024 12:00AM
|
Voyager Therapeutics, Inc.
|
35K
|
193.00
|
Open
|
|
Apr 16th, 2024 12:17AM
|
Apr 16th, 2024 11:52AM
|
Voyager Therapeutics (Nasdaq: VYGR) is a biotechnology company dedicated to breaking through barriers in gene therapy and neurology. The potential of both disciplines has been constrained by delivery challenges; Voyager is leveraging cutting-edge expertise in capsid discovery and deep neuropharmacology capabilities to address these constraints. Voyager’s TRACER™ AAV capsid discovery platform has generated novel capsids with high target delivery and blood-brain barrier penetration at low doses, potentially addressing the narrow therapeutic window associated with conventional gene therapy delivery vectors. This platform is fueling alliances with Alexion (AstraZeneca Rare Disease); Novartis Pharma AG; Neurocrine Biosciences, Inc. and Sangamo Therapeutics, Inc., as well as multiple programs in Voyager’s own pipeline. Voyager’s pipeline includes wholly-owned and collaborative preclinical programs in Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and other diseases of the central nervous system, with a focus on validated targets and biomarkers to enable a path to rapid potential proof-of-biology. For more information, visit www.voyagertherapeutics.com.
|
Open
|
Gene Therapy, biotechnology, adeno associated virus, Research, Parkinson's Disease, Huntington's Disease, vector engineering, SF9, Alzheimer's disease, ALS, Amyotrophic Lateral Sclerosis, Friedrich's Ataxia, SOD-1, Tauopathies, gene therapy, Neurology, Neuropharmacology, and CNS
|
Open
|
64 Sidney St
|
Cambridge
|
Massachusetts
|
US
|
02139
|
|
Voyager Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:vygr
|
5074064
|
Apr 15th, 2024 12:00AM
|
Voyager Therapeutics, Inc.
|
35K
|
193.00
|
Open
|
|
Apr 15th, 2024 12:05AM
|
Apr 15th, 2024 05:33PM
|
Voyager Therapeutics (Nasdaq: VYGR) is a biotechnology company dedicated to breaking through barriers in gene therapy and neurology. The potential of both disciplines has been constrained by delivery challenges; Voyager is leveraging cutting-edge expertise in capsid discovery and deep neuropharmacology capabilities to address these constraints. Voyager’s TRACER™ AAV capsid discovery platform has generated novel capsids with high target delivery and blood-brain barrier penetration at low doses, potentially addressing the narrow therapeutic window associated with conventional gene therapy delivery vectors. This platform is fueling alliances with Alexion (AstraZeneca Rare Disease); Novartis Pharma AG; Neurocrine Biosciences, Inc. and Sangamo Therapeutics, Inc., as well as multiple programs in Voyager’s own pipeline. Voyager’s pipeline includes wholly-owned and collaborative preclinical programs in Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and other diseases of the central nervous system, with a focus on validated targets and biomarkers to enable a path to rapid potential proof-of-biology. For more information, visit www.voyagertherapeutics.com.
|
Open
|
Gene Therapy, biotechnology, adeno associated virus, Research, Parkinson's Disease, Huntington's Disease, vector engineering, SF9, Alzheimer's disease, ALS, Amyotrophic Lateral Sclerosis, Friedrich's Ataxia, SOD-1, Tauopathies, gene therapy, Neurology, Neuropharmacology, and CNS
|
Open
|
64 Sidney St
|
Cambridge
|
Massachusetts
|
US
|
02139
|
|
Voyager Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:vygr
|
5074064
|
Apr 14th, 2024 12:00AM
|
Voyager Therapeutics, Inc.
|
35K
|
193.00
|
Open
|
|
Apr 13th, 2024 11:53PM
|
Apr 13th, 2024 11:53PM
|
Voyager Therapeutics (Nasdaq: VYGR) is a biotechnology company dedicated to breaking through barriers in gene therapy and neurology. The potential of both disciplines has been constrained by delivery challenges; Voyager is leveraging cutting-edge expertise in capsid discovery and deep neuropharmacology capabilities to address these constraints. Voyager’s TRACER™ AAV capsid discovery platform has generated novel capsids with high target delivery and blood-brain barrier penetration at low doses, potentially addressing the narrow therapeutic window associated with conventional gene therapy delivery vectors. This platform is fueling alliances with Alexion (AstraZeneca Rare Disease); Novartis Pharma AG; Neurocrine Biosciences, Inc. and Sangamo Therapeutics, Inc., as well as multiple programs in Voyager’s own pipeline. Voyager’s pipeline includes wholly-owned and collaborative preclinical programs in Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and other diseases of the central nervous system, with a focus on validated targets and biomarkers to enable a path to rapid potential proof-of-biology. For more information, visit www.voyagertherapeutics.com.
|
Open
|
Gene Therapy, biotechnology, adeno associated virus, Research, Parkinson's Disease, Huntington's Disease, vector engineering, SF9, Alzheimer's disease, ALS, Amyotrophic Lateral Sclerosis, Friedrich's Ataxia, SOD-1, Tauopathies, gene therapy, Neurology, Neuropharmacology, and CNS
|
Open
|
64 Sidney St
|
Cambridge
|
Massachusetts
|
US
|
02139
|
|
Voyager Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:vygr
|
5074064
|
Apr 13th, 2024 12:00AM
|
Voyager Therapeutics, Inc.
|
35K
|
193.00
|
Open
|
|
Apr 12th, 2024 11:45PM
|
Apr 13th, 2024 12:18PM
|
Voyager Therapeutics (Nasdaq: VYGR) is a biotechnology company dedicated to breaking through barriers in gene therapy and neurology. The potential of both disciplines has been constrained by delivery challenges; Voyager is leveraging cutting-edge expertise in capsid discovery and deep neuropharmacology capabilities to address these constraints. Voyager’s TRACER™ AAV capsid discovery platform has generated novel capsids with high target delivery and blood-brain barrier penetration at low doses, potentially addressing the narrow therapeutic window associated with conventional gene therapy delivery vectors. This platform is fueling alliances with Alexion (AstraZeneca Rare Disease); Novartis Pharma AG; Neurocrine Biosciences, Inc. and Sangamo Therapeutics, Inc., as well as multiple programs in Voyager’s own pipeline. Voyager’s pipeline includes wholly-owned and collaborative preclinical programs in Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and other diseases of the central nervous system, with a focus on validated targets and biomarkers to enable a path to rapid potential proof-of-biology. For more information, visit www.voyagertherapeutics.com.
|
Open
|
Gene Therapy, biotechnology, adeno associated virus, Research, Parkinson's Disease, Huntington's Disease, vector engineering, SF9, Alzheimer's disease, ALS, Amyotrophic Lateral Sclerosis, Friedrich's Ataxia, SOD-1, Tauopathies, gene therapy, Neurology, Neuropharmacology, and CNS
|
Open
|
64 Sidney St
|
Cambridge
|
Massachusetts
|
US
|
02139
|
|
Voyager Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:vygr
|
5074064
|
Apr 12th, 2024 12:00AM
|
Voyager Therapeutics, Inc.
|
35K
|
193.00
|
Open
|
|
Apr 11th, 2024 11:52PM
|
Apr 12th, 2024 09:14AM
|
Voyager Therapeutics (Nasdaq: VYGR) is a biotechnology company dedicated to breaking through barriers in gene therapy and neurology. The potential of both disciplines has been constrained by delivery challenges; Voyager is leveraging cutting-edge expertise in capsid discovery and deep neuropharmacology capabilities to address these constraints. Voyager’s TRACER™ AAV capsid discovery platform has generated novel capsids with high target delivery and blood-brain barrier penetration at low doses, potentially addressing the narrow therapeutic window associated with conventional gene therapy delivery vectors. This platform is fueling alliances with Alexion (AstraZeneca Rare Disease); Novartis Pharma AG; Neurocrine Biosciences, Inc. and Sangamo Therapeutics, Inc., as well as multiple programs in Voyager’s own pipeline. Voyager’s pipeline includes wholly-owned and collaborative preclinical programs in Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and other diseases of the central nervous system, with a focus on validated targets and biomarkers to enable a path to rapid potential proof-of-biology. For more information, visit www.voyagertherapeutics.com.
|
Open
|
Gene Therapy, biotechnology, adeno associated virus, Research, Parkinson's Disease, Huntington's Disease, vector engineering, SF9, Alzheimer's disease, ALS, Amyotrophic Lateral Sclerosis, Friedrich's Ataxia, SOD-1, Tauopathies, gene therapy, Neurology, Neuropharmacology, and CNS
|
Open
|
64 Sidney St
|
Cambridge
|
Massachusetts
|
US
|
02139
|
|
Voyager Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|